MorphoSys and partners drop MOR106 development for atopic dermatitis

30 October 2019
2019_biotech_research_lab_big

Germany’s MorphoSys (FSE: MOR) and Belgium’s Galapagos (Euronext: GLPG) today announced the end of the clinical development program of MOR106 in atopic dermatitis.

The joint decision of all three involved parties, Galapagos, MorphoSys and Novartis (NOVN: DE), was based on an interim analysis for futility that was performed in the Phase II GUANA trial. The analysis detected a low probability to meet the primary endpoint of the study, defined as the percentage change in the eczema area and severity index (EASI) score. The decision was based on a lack of efficacy and not on safety concerns.

Despite the announcement, MorphoSys shares were up more than 2% at 97.05 euros, and Galapagos gained 1.97% to 162.85 euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology